EP433 The efficacy of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage IB-IIA cervical cancer. (1st November 2019)

• Record Type: Journal Article
• Authors: Wang, Y; Lin, H; Lee, P; Huang, C; Wu, C
• Is Part Of: International journal of gynecological cancer. Volume 29(2019)Supplement 4
• Page Start: A280
• Page End: A280
• Publication Date: 2019-11-01
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2019-ESGO.492
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: The aim of this study is to evaluate the efficacy of adjuvant chemotherapy following radical hysterectomy (RH) for women with intermediate risk stage IB-IIA cervical cancer. Methodology: From January 2001 to December 2015, a total of 97 patients of FIGO stage IB-IIA cervical cancer having intermediate risk after radical hysterectomy and pelvic lymphadenectomy were enrolled in this study. Among these patients, 21 patients underwent adjuvant radiotherapy (RH+RT, N=21), 24 patients had cisplatin-based adjuvant chemotherapy (RH+CT, N=24), and 52 patients had surgery only (RH only, N=52). Disease-free survival (DFS) and overall survival (OS) were evaluated with Kaplan-Meier method and the log-rank test. Cox´s proportional-hazards regression model were used to evaluate the impact of prognostic factors in multivariant analysis. Results: The percentage of histology distribution in 97 patients were 70.1% (68 patients) squamous cell carcinoma and 29.9% (29 patients) non-squamous cell carcinoma. The mean 5-year DFS rate is 88.1% in RH only group, 82.6% in RH+CT group and 70.8% in RH+RT group (P=0.350), respectively. The 5-year OS rate is 95.8% in RH only group, 91.3% in RH+CT group and 85.4% in RH+RT group (P=0.343), respectively. In the univariant analysis, histologic type seemed to be a prognostic factor for recurrence (P=0.014); however, it only showed borderline significance in multivariant analysis (P=0.053). Conclusion: Concerning the long-term and irreversible toxicities related to adjuvant radiotherapy following RH, cisplatin-based adjuvant chemotherapy or close surveillance for patients with intermediate-risk cervical cancer after RH showed non-inferior survival impact as compared to adjuvant radiotherapy. Therefore, adjuvant chemotherapy or close surveillance can be an alternative management for patients having intermediate risk of recurrence following radical surgery. Disclosure: Nothing to disclose.